Goldline
This article was originally published in The Tan Sheet
Executive Summary
April 8 warning letter from FDA charges that labeling for Goldline Bacitracin Ointment makes unsubstantiated claims such as "aids in the healing of minor burns, cuts [and] scrapes." The letter also cites the firm for not bearing an appropriate statement of identity on the principal display panel for Goldline Vitamin E Cream. Goldline said it informed FDA on April 20 that it told the products' manufacturer, Clay Park of Bronx, New York, of the deficiencies and that Clay Park will work to bring the items into compliance.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning